C-Reactive Protein (CRP) ELISA Kit

Details for Product No. ABIN612674, Supplier: Log in to see
  • crp
  • PTX1
  • AI255847
  • Aa1249
  • Ab1-341
  • Ab2-196
  • Ac1-114
  • Ac1262
  • Ac2-069
  • Ba2-693
  • APCS
  • 0610010I23Rik
  • AW743261
  • C77570
  • CRP2
  • CRP4
  • Crp
  • ESP1
  • Hlp
  • CRP
  • GRP-CB
  • C-reactive protein
  • C-reactive protein, pentraxin-related
  • cysteine rich protein 2
  • glutamine/glutamic acid-rich protein A
  • crp
  • CRP
  • Crp
  • Crip2
  • Grpcb
Cow (Bovine) C-Reactive Protein ELISA Kit
Kits with alternative reactivity to:
Method Type
Sandwich ELISA
Minimum Detection Limit
100 pg/mL
Log in to see
Supplier Product No.
Log in to see
Purpose The AssayMax Human C-Reactive Protein ELISA kit is designed for detection of human CRP in plasma, serum and cell culture supernatants
Brand AssayMax
Sample Type Plasma, Cell Culture Supernatant
Analytical Method Quantitative
Detection Method Colorimetric
Components CRP Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a murine antibody against CRP. Sealing Tapes: Each kit contains 3 pre-cut, pressure-sensitive sealing tapes that can be cut to fit the format of the individual assay. 1 CRP Standard: Human CRP in a buffered protein base (16 ng, lyophilized). Biotinylated CRP Antibody (100x): A 100-fold biotinylated polyclonal antibody against CRP (80µl). EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml). Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml). Streptavidin-Peroxidase Conjugate (SP Conjugate): A 100-fold concentrate (80µl). Chromogen Substrate: A ready-to-use stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml). Stop Solution: A 0.5 N hydrochloric acid to stop the chromogen substrate reaction (12 ml).
Material not included Microplate reader capable of measuring absorbance at 450 nm. Pipettes (1-20 µL, 20-200 µL, 200-1000µLand multiple channel pipette) Deionized or distilled reagent grade water
Background C-Reactive Protein (CRP) is a liver protein composed of five identical nonglycosylated subunits, with a total molecular weight of 105 kDa. CRP has a variety of powerful effects related to immunology, inflammation, and coagulation. As a marker of low-level inflammation, CRP appears to predict future cardiovascular disease events among apparently healthy individuals. High plasma concentration of CRP was associated with increased risk of stroke, myocardial infarction, and peripheral vascular disease. CRP has also been associated with increased risks of fatal coronary events among high-risk male smokers and incident coronary disease among the elderly. Studies have established the prognostic usefulness of CRP in the setting of angina. Originally used as a marker of acute inflammation, CRP has become a leading candidate as the measure of choice for estimating the inflammatory component of cardiovascular disease risk.
Research Area Serum/Plasma Proteins, Inflammation
Pathways Carbohydrate Homeostasis
Sample Volume 50 μL
Assay Time < 4 h
Plate Pre-coated
Protocol This assay employs a quantitative sandwich enzyme immunoassay technique that measures CRP in less than 4 hours. A murine antibody specific for CRP has been pre-coated onto a microplate. CRP in standards and samples is sandwiched by the immobilized antibody and biotinylated polyclonal antibody specific for CRP, which is recognized by a streptavidin-peroxidase conjugate. All unbound material is then washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.
Reagent Preparation

Freshly dilute all reagents and bring all reagents to room temperature before use. If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. EIA Diluent Concentrate (10x): Dilute the EIA Diluent 1:10 with reagent grade water. Store for up to 1 month at 2-8°C. CRP Standard: Reconstitute the 16 ng of human CRP Standard with 1.0 ml of EIA Diluent to generate a 16 ng/ml of solution. Allow the standard to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting the Standard solution (16 ng/ml) twofold with equal volume of EIA Diluent to 2 produce 8, 4, 2, 1, 0.5 and 0.25 ng/ml. EIA Diluent serves as the zero standard (0 ng/ml). Any remaining solution should be frozen at -20°C. Standard Point Dilution [CRP] (ng/ml) P1 1 part Standard (16 ng/ml) 16.000 P2 1 part P1 + 1 part EIA Diluent 8.000 P3 1 part P2 + 1 part EIA Diluent 4.000 P4 1 part P3 + 1 part EIA Diluent 2.000 P5 1 part P4 + 1 part EIA Diluent 1.000 P6 1 part P5 + 1 part EIA Diluent 0.500 P7 1 part P6 + 1 part EIA Diluent 0.250 P8 EIA Diluent 0.000 Biotinylated CRP Antibody (100x): Spin down the antibody briefly and dilute the desired amount of the antibody 1:100 with EIA Diluent. Any remaining solution should be frozen at -20°C. Wash Buffer Concentrate (20x): Dilute the Wash Buffer Concentrate 1:20 with reagent grade water. SP Conjugate (100x): Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 1:100 with EIA Diluent. Any remaining solution should be frozen at -20°C.

Sample Collection Plasma: Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 2000 x g for 10 minutes and assay. Dilute samples 1:1000 with EIA Diluent. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles. (EDTA or Heparin can also be used as anticoagulant.) Serum: Samples should be collected into a serum separator tube. After clot formation, centrifuge samples at 2000 x g for 10 minutes. Remove serum and assay. Dilute samples 1:1000 into EIA Diluent. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles. Cell Culture Supernatants: Centrifuge cell culture media at 2000 x g for 10 minutes to remove debris. Collect supernatants and assay. The samples can be stored at -20°C or below. Avoid repeated freeze-thaw cycles.
Assay Procedure

Prepare all reagents, working standards and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20 - 30 °C). Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccant inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator. Add 50 µL of Standard or sample per well. Cover wells with a sealing tape and incubate for two hours. Start the timer after the last sample addition. Wash five times with 200 µL of Wash Buffer manually. Invert the plate each time and decant the contents, hit it 4-5 times on absorbent paper towel to completely remove the liquid. Add 50 µL of Biotinylated CRP Antibody to each well and incubate for 30 minutes. Wash a microplate as described above. Add 50 µL of Streptavidin-Peroxidase Conjugate per well and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance. Wash a microplate as described above. Add 50 µL of Chromogen Substrate per well and incubate for about 10 minutes or till the optimal color density develops. Gently tap the plate to ensure thorough mixing and break the bubbles in the well with pipette tip. Add 50 µL of Stop Solution to each well. The color will change from blue to yellow. Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Calculation of Results

Calculate the mean value of the duplicate or triplicate readings for each standard and sample. To generate a Standard Curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance on the y-axis. The best-fit line can be determined by regression analysis using log-log or four-parameter logistic curve-fit. Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor. Standard Curve The curve is used for illustration only. A standard curve should be generated each time the assay is performed.

Assay Precision Intra-assay and inter-assay coefficients of variation were 5.4 % and 7.7% respectively.
Restrictions For Research Use only
Handling Advice The kit should not be used beyond the expiration date.
Storage 4 °C/-20 °C
Storage Comment Store kit at 2-8°C or -20°C upon arrival up to the expiration date. Opened EIA Diluent may be stored for up to 1 month at 2-8°C. Store reconstituted reagents at -20°C or below. Opened unused strip wells may return to the foil pouch with the desiccant pack, reseal along zip-seal. May be stored for up to 1 month in a vacuum desiccator.
Supplier Images
ELISA image for C-Reactive Protein (CRP) ELISA Kit (ABIN612674) C-Reactive Protein (CRP) ELISA Kit
Product cited in: Nicholson, Chisenga, Siame, Kasonka, Filteau: "Growth and health outcomes at school age in HIV-exposed, uninfected Zambian children: follow-up of two cohorts studied in infancy." in: BMC pediatrics, Vol. 15, pp. 66, 2015 (PubMed).

James, Friis, Woodd, Rehman, PrayGod, Kelly, Koethe, Filteau: "Minimal impact of an iron-fortified lipid-based nutrient supplement on Hb and iron status: a randomised controlled trial in malnourished HIV-positive African adults starting antiretroviral therapy." in: The British journal of nutrition, pp. 1-11, 2015 (PubMed).

Alkhateeb, Leitzel, Ali, Campbell-Baird, Evans, Fuchs, Köstler, Lipton, Connor: "Elevation in inflammatory serum biomarkers predicts response to trastuzumab-containing therapy." in: PLoS ONE, Vol. 7, Issue 12, pp. e51379, 2013 (PubMed).

Kotani, Yamada, Miyamoto, Ishibashi, Taniguchi, Gugliucci: "Influence of atorvastatin on serum amyloid A-low density lipoprotein complex in hypercholesterolemic patients." in: Pharmacological reports : PR, Vol. 64, Issue 1, pp. 212-6, 2012 (PubMed).

Background publications Ridker, Buring, Shih, Matias, Hennekens: "Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women." in: Circulation, Vol. 98, Issue 8, pp. 731-3, 1998 (PubMed).

Ridker, Cushman, Stampfer, Tracy, Hennekens: "Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease." in: Circulation, Vol. 97, Issue 5, pp. 425-8, 1998 (PubMed).

Ridker, Cushman, Stampfer, Tracy, Hennekens: "Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men." in: The New England journal of medicine, Vol. 336, Issue 14, pp. 973-9, 1997 (PubMed).

Tracy, Lemaitre, Psaty, Ives, Evans, Cushman, Meilahn, Kuller: "Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project." in: Arteriosclerosis, thrombosis, and vascular biology, Vol. 17, Issue 6, pp. 1121-7, 1997 (PubMed).

Kuller, Tracy, Shaten, Meilahn: "Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial." in: American journal of epidemiology, Vol. 144, Issue 6, pp. 537-47, 1996 (PubMed).

Liuzzo, Biasucci, Gallimore, Grillo, Rebuzzi, Pepys, Maseri: "The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina." in: The New England journal of medicine, Vol. 331, Issue 7, pp. 417-24, 1994 (PubMed).

Did you look for something else?